NHS

Views & Analysis

VPAS 2024: What should industry consider next time?

The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded medicines spend; the 2019 Voluntary Scheme for Branded Medicines Pricing

News

NHS hospitals join with NVIDIA, using AI to interpret radiol...

Graphics card specialist NVIDIA and King’s College London have announced they are partnering to build an artificial intelligence (AI) platform that could allow specialists in the NHS to tra

Views & Analysis

Market access round-up: the UK opens up to innovation

When it comes to market access in the UK, the public’s eye has mostly been on the ongoing furore over Vertex’s cystic fibrosis drug

Views & Analysis

Opening the digital door to the NHS

The UK government recently announced plans to open a ‘digital front door’ to the NHS by giving patie

Views & Analysis

Shifting the paradigm from “disease care” to health care

Cat Oyler, vice president, global public health, tuberculosis at Johnson & Johnson, explains that by shifting focus to prevention, we can help to both reduce pressure on an increasingly

Views & Analysis

UK pharma negotiating choppy seas during Brexit, says ABPI’s...

pharmaphorum caught up with Erik Nordkamp, outgoing president of the Association of the British Pharmaceutical Industry (ABPI), who has also changed role at Pfizer to become the organisatio

VPAS 2024: What should industry consider next time?

NHS hospitals join with NVIDIA, using AI to interpret radiol...

Market access round-up: the UK opens up to innovation

Opening the digital door to the NHS

Shifting the paradigm from “disease care” to health care

UK pharma negotiating choppy seas during Brexit, says ABPI’s...

UK offers meningitis jab to young people after outbreak

Discover a new era of healthcare panel engagement: Grounded ...

NHS

Editor's Picks